Share This Page
Suppliers and packagers for generic pharmaceutical drug: epinephrine
✉ Email this page to a colleague
epinephrine
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Armstrong Pharms | PRIMATENE MIST | epinephrine | AEROSOL, METERED;INHALATION | 205920 | NDA | Armstrong Pharmaceuticals, Inc. | 17270-5512-0 | 12 CARTON in 1 PACKAGE (17270-5512-0) / 1 INHALER in 1 CARTON / 160 AEROSOL in 1 INHALER | 2018-12-14 |
| Armstrong Pharms | PRIMATENE MIST | epinephrine | AEROSOL, METERED;INHALATION | 205920 | NDA | Armstrong Pharmaceuticals, Inc. | 17270-5530-0 | 1 INHALER in 1 CARTON (17270-5530-0) / 160 AEROSOL in 1 INHALER | 2018-12-14 |
| Viatris | EPI E Z PEN JR | epinephrine | INJECTABLE;INTRAMUSCULAR | 019430 | NDA AUTHORIZED GENERIC | Viatris Specialty LLC | 49502-101-02 | 2 CONTAINER in 1 CARTON (49502-101-02) / 1 SYRINGE, GLASS in 1 CONTAINER (49502-101-01) / .3 mL in 1 SYRINGE, GLASS | 2016-12-15 |
| Viatris | EPI E Z PEN JR | epinephrine | INJECTABLE;INTRAMUSCULAR | 019430 | NDA AUTHORIZED GENERIC | Viatris Specialty LLC | 49502-102-02 | 2 CONTAINER in 1 CARTON (49502-102-02) / 1 SYRINGE, GLASS in 1 CONTAINER (49502-102-01) / .3 mL in 1 SYRINGE, GLASS | 2016-12-15 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for generic pharmaceutical drug: epinephrine
Executive summary
Epinephrine is a widely sourced, commodity injectables API with numerous approved finished-dose suppliers in the US. Patent-driven supplier exclusivity is limited in practice because epinephrine’s key reference products and many market formulations rely on mature, low-patent-density estates, while FDA approval for generics is supported by established manufacturing know-how and compendial/USP specifications. Competitive differentiation is mainly driven by supply capacity, container closure system (prefilled vs. vial vs. cartridge), concentration (e.g., 0.1 mg/mL, 1 mg/mL), and device integration (auto-injectors), not by strong brand exclusivity.
What matters for procurement and partnering
- US supplier set is dominated by multiple ANDA/authorized generic manufacturers for solution injectables and a smaller set of qualified producers for device-integrated products (auto-injectors).
- IP barriers are generally modest for simple epinephrine solutions, but higher for device-specific formulations, packaging systems, and delivery mechanisms.
- Risk shifts from “patent lockout” to “supply continuity,” especially for autoinjectors and specific package formats.
Epinephrine suppliers (API and finished dose) in the US: Which companies sell epinephrine injection?
Epinephrine supply splits into two practical procurement categories: (1) epinephrine API and (2) finished-dose epinephrine injections and device-integrated products.
What are the main finished-dose formats by supplier model?
-
Vial and prefilled syringe injectables
- Supplied through generic and authorized generic channels.
- Specification adherence is typically USP/compendial oriented, with container closure and labeling as main differentiators.
-
Auto-injectors (device-integrated epinephrine)
- Supplied by fewer firms because the manufacturing package includes a drug-device combination and device performance validation.
- These products usually command a more concentrated supplier base and higher qualification burden.
How to map “suppliers” for procurement quickly
- For contracting and onboarding, separate:
- API suppliers (chemical manufacture of epinephrine)
- Finished dose manufacturers (fill-and-finish and label)
- Device manufacturers and integrators (for auto-injectors and cartridges)
Which companies supply epinephrine auto-injectors in the US (brand and generic)?
Auto-injectors are the highest-friction segment due to device integration and validation.
Typical US market structure
- Brand reference: historically dominated by established device-integrated manufacturers.
- Generics/biosimilar-equivalents analog: the market sees competition through drug-device regulatory pathways rather than “generic-to-biologic” mechanics.
Supplier implications
- Qualification focuses on:
- device reliability (activation force, needle penetration consistency, spray pattern)
- stability of epinephrine in the specific container closure
- manufacturing traceability and lot-to-lot performance testing
What patents protect epinephrine injections and what does that mean for supplier access?
Epinephrine’s core molecule is old, and its basic injectable solutions have low remaining patent life in most jurisdictions. The supplier landscape is therefore more constrained by manufacturing capacity than by active primary patents.
Where patent protection can still matter
- Specific concentrations and presentation (packaging format, fill size)
- Device integration (auto-injector mechanics and delivery system claims)
- Formulation and stability systems (if claims exist for a specific solution composition beyond compendial grades)
- Method-of-manufacture for fill-and-finish and device assembly
Practical result
- For many “simple solution” epinephrine SKUs, supplier entry barriers are primarily regulatory and operational, not exclusive IP.
How many suppliers are approved for epinephrine injection: what drives the number of manufacturers?
The number of suppliers for epinephrine injectables is driven by:
- ANDA/abbreviated approval feasibility for established products
- Availability of reliable sterile manufacturing capacity
- Ability to meet stability and container closure requirements
- Device qualification barriers for auto-injectors
Key determinant: sterility and container closure
Even when the active drug is a commodity, sterile fill-finish constraints can reduce the practical supplier count.
What is the Orange Book status of epinephrine injection products (and how does it affect suppliers)?
Orange Book status determines whether a finished-dose product is protected by listed patents that can affect generic entry timing.
Supplier effect
- Products with fewer active listed patents tend to have more generic/authorized generic availability.
- Products with device- and packaging-related listed patents may face later entry for that specific SKU format, even if the drug substance is not protected.
When does epinephrine lose exclusivity and when can generics enter?
For most classic epinephrine injection formats, the exclusivity and patent lead time has largely run, which is why multiple suppliers exist. For auto-injectors, entry timing can be influenced by:
- device-specific patents
- formulation and stability claims tied to the device
- settlement agreements that can delay market entry even after initial patent expiration
Timing reality for procurement
- For epinephrine injectables, market availability is typically not limited by exclusivity in the way it is for newer specialty drugs.
- Supplier shortages are more often linked to manufacturing disruptions and device qualification bottlenecks.
What Paragraph IV challenges exist for epinephrine injectables, and which generics are at risk?
In practice, epinephrine’s patent landscape is mature. Where disputes occur, they tend to relate to:
- device-integrated products
- specific presentation SKUs
- packaging system claims
Generic entry risk assessment
- For simple solutions: lower probability of late-stage exclusivity-driven blocking.
- For auto-injectors: higher likelihood of litigation and settlement-driven market dynamics.
What formulation and packaging patents affect epinephrine supply (vials vs. prefilled syringes vs. cartridges)?
Even with mature drug substance patents, packaging and device assembly can drive separate claim sets.
Areas that can create SKU-level differences
- Concentration (e.g., 0.1 mg/mL vs. 1 mg/mL)
- Volume and fill amount
- Container closure system (glass type, elastomer compatibility)
- Stability enhancers if included beyond compendial norms
- Device cartridge design and needle/spring timing in auto-injectors
What FDA status do epinephrine suppliers hold: NDA, ANDA, and device-combination approvals?
For procurement, FDA status shapes where and how a product can be substituted.
What buyers should track
- Drug approval type (NDA vs. ANDA vs. device-drug combination)
- CFR and labeling for indications and administration instructions
- Stability and storage requirements by lot and package configuration
- Recall and inspection history for sterile manufacturing
Competitive landscape: how do epinephrine manufacturers compare by format and supply continuity?
Vial and prefilled syringe solutions
- Competitive set tends to be broad.
- Differentiation: packaging, concentration, and availability.
Auto-injectors
- Concentration is higher.
- Differentiation: device design, training/labeling, and validated performance under regulatory standards.
Manufacturing and IP barriers for epinephrine suppliers: what causes shortages?
Epinephrine supply issues usually trace to:
- sterile manufacturing capacity constraints
- component supply (needles, springs, carriers, elastomers)
- cold-chain or stability management requirements for specific presentations
- regulatory quality system failures that temporarily suspend production
Device supply chain bottleneck
For auto-injectors, the limiting factor is often the integrated device subcomponents, not the API.
Key Takeaways
- Epinephrine is a broadly available injectable commodity with a supplier landscape dominated by finished-dose and device-integrated manufacturers rather than by active IP exclusivity.
- Supplier differentiation is driven by presentation (vial/prefill vs. auto-injector), concentration, container closure, and device integration requirements.
- For procurement and partnering, supply continuity and device qualification constraints are typically higher-impact than patent lockout.
- Patent-driven blocking is more likely for specific device-packaging SKUs than for basic epinephrine solutions.
FAQs
1) Which firms manufacture epinephrine injection vials and prefilled syringes in the US?
A broad set of FDA-approved manufacturers supplies epinephrine injections, with competition primarily determined by sterile fill-finish capacity and packaging compatibility.
2) Which companies supply epinephrine auto-injectors (0.3 mg and 0.15 mg equivalents) in the US?
Auto-injectors are concentrated among fewer qualified drug-device manufacturers because device integration and performance validation raise barriers.
3) Do epinephrine injection generics face major patent litigation risks?
For common solution presentations, major patent-driven blocking is uncommon due to epinephrine’s mature patent estate; higher risks can occur for specific device-integrated SKUs.
4) What packaging requirements matter most for epinephrine supplier qualification?
Container closure system compatibility and validated stability are key for sterile epinephrine solutions and for device-integrated formulations.
5) What is the biggest driver of epinephrine shortages?
The biggest driver is usually manufacturing or component constraints in sterile fill-finish and device subassemblies rather than FDA exclusivity.
More… ↓
